On April 6 2017 the General Court rendered its judgment in NIMORAL (Case T-49/16). The case concerned an application by Azanta A/S for the trademark NIMORAL in relation to pharmaceutical preparations for enhancing the effect of radiotherapy on cancer patients in Class 5. The application was opposed by Novartis AG on the basis of the earlier EU trademark NEORAL, also registered in Class 5 in...

Issue 67

Take up a trial to view this content. Your three-week free trial includes:

  • Extensive access to the World Trademark Review site
  • The editor's weekly review by email
  • Free magazine issue delivered direct to you
Trial now Login

Share this article